Literature DB >> 9105693

Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties.

S M Sendobry1, J A Cornicelli, K Welch, T Bocan, B Tait, B K Trivedi, N Colbry, R D Dyer, S J Feinmark, A Daugherty.   

Abstract

1. 15-Lipoxygenase (15-LO) has been implicated in the pathogenesis of atherosclerosis because of its localization in lesions and the many biological activities exhibited by its products. To provide further evidence for a role of 15-LO, the effects of PD 146176 on the development of atherosclerosis in cholesterol-fed rabbits were assessed. This novel drug is a specific inhibitor of the enzyme in vitro and lacks significant non specific antioxidant properties. 2. PD 146176 inhibited rabbit reticulocyte 15-LO through a mixed noncompetitive mode with a Ki of 197 nM. The drug had minimal effects on either copper or 2,2'-azobis(2-amidinopropane)hydrochloride (ABAP) induced oxidation of LDL except at concentrations 2 orders higher than the Ki. 3. Control New Zealand rabbits were fed a high-fat diet containing 0.25% wt./wt. cholesterol; treated animals received inhibitor in this diet (175 mg kg-1, b.i.d.). Plasma concentrations of inhibitor were similar to the estimated Ki (197 nM). During the 12 week study, there were no significant differences in weight gain haematocrit, plasma total cholesterol concentrations, or distribution of lipoprotein cholesterol. 4. The drug plasma concentrations achieved in vivo did not inhibit low-density lipoprotein (LDL) oxidation in vitro. Furthermore, LDL isolated from PD 146176-treated animals was as susceptible as that from controls to oxidation ex vivo by either copper or ABAP. 5. PD 146176 was very effective in suppressing atherogenesis, especially in the aortic arch where lesion coverage diminished from 15 +/- 4 to 0% (P < 0.02); esterified cholesterol content was reduced from 2.1 +/- 0.7 to 0 micrograms mg-1 (P < 0.02) in this region. Immunostainable lipid-laden macrophages present in aortic intima of control animals were totally absent in the drug-treated group. 6. Results of these studies are consistent with a role for 15-LO in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105693      PMCID: PMC1564586          DOI: 10.1038/sj.bjp.0701007

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  At last, direct evidence that lipoxygenases play a role in atherogenesis.

Authors:  D Steinberg
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

2.  Signaling cascades for δ-opioid receptor-mediated inhibition of GABA synaptic transmission and behavioral antinociception.

Authors:  Zhi Zhang; Zhizhong Z Pan
Journal:  Mol Pharmacol       Date:  2011-12-05       Impact factor: 4.436

3.  PPARs and lipid ligands in inflammation and metabolism.

Authors:  Gregory S Harmon; Michael T Lam; Christopher K Glass
Journal:  Chem Rev       Date:  2011-10-12       Impact factor: 60.622

4.  Membrane-dependent Activities of Human 15-LOX-2 and Its Murine Counterpart: IMPLICATIONS FOR MURINE MODELS OF ATHEROSCLEROSIS.

Authors:  Gunes Bender; Erin E Schexnaydre; Robert C Murphy; Charis Uhlson; Marcia E Newcomer
Journal:  J Biol Chem       Date:  2016-07-19       Impact factor: 5.157

5.  ROS-dependent Syk and Pyk2-mediated STAT1 activation is required for 15(S)-hydroxyeicosatetraenoic acid-induced CD36 expression and foam cell formation.

Authors:  Sivareddy Kotla; Nikhlesh K Singh; James G Traylor; A Wayne Orr; Gadiparthi N Rao
Journal:  Free Radic Biol Med       Date:  2014-08-23       Impact factor: 7.376

6.  Elevated endothelial nitric oxide bioactivity and resistance to angiotensin-dependent hypertension in 12/15-lipoxygenase knockout mice.

Authors:  Peter B Anning; Barbara Coles; Alexandra Bermudez-Fajardo; Patricia E M Martin; Bruce S Levison; Stanley L Hazen; Colin D Funk; Hartmut Kühn; Valerie B O'Donnell
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  The potential of 12/15-lipoxygenase inhibitors in stroke therapy.

Authors:  Klaus van Leyen; Theodore R Holman; David J Maloney
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

8.  The transcription factor CREB enhances interleukin-17A production and inflammation in a mouse model of atherosclerosis.

Authors:  Sivareddy Kotla; Nikhlesh K Singh; Mark R Heckle; Gabor J Tigyi; Gadiparthi N Rao
Journal:  Sci Signal       Date:  2013-09-17       Impact factor: 8.192

9.  Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses.

Authors:  Yang Ou; Shang-Jui Wang; Dawei Li; Bo Chu; Wei Gu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

10.  12/15-Lipoxygenase mediates high-fat diet-induced endothelial tight junction disruption and monocyte transmigration: a new role for 15(S)-hydroxyeicosatetraenoic acid in endothelial cell dysfunction.

Authors:  Venkatesh Kundumani-Sridharan; Elena Dyukova; Dale E Hansen; Gadiparthi N Rao
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.